GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Float Percentage Of Total Shares Outstanding

Outlook Therapeutics (FRA:41O) Float Percentage Of Total Shares Outstanding : 83.94% (As of Jun. 08, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Outlook Therapeutics's float shares is 19.65 Mil. Outlook Therapeutics's total shares outstanding is 23.41 Mil. Outlook Therapeutics's float percentage of total shares outstanding is 83.94%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Outlook Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Outlook Therapeutics's Institutional Ownership is 5.67%.

Outlook Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Outlook Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=19.65/23.41
=83.94%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics (FRA:41O) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
VOR BIVI NVCT GRPH FHTX RIGL RPTX VRCA CYDY MRSN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
OTLK:USA 41ON:Germany
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Website
https://www.outlooktherapeutics.com
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines